London, United Kingdom–(Newsfile Corp. – April 23, 2025) – Edison issues report on Aamal Company (QSE: AHCS).
Aamal Company is a highly diversified conglomerate in Qatar operating across four business segments: Trading and Distribution, Industrial Manufacturing, Property and Managed Services. The company offers exposure to Qatar’s forecast strong economic growth in the medium term, especially in the key non-hydrocarbon sectors, due to an increase in government spending to diversify the country away from its dependence on liquefied natural gas (LNG) exports. Aamal trades at a 26% discount relative to peers in the Middle East and North Africa (MENA) region on an FY25e EV/EBITDA basis and at a 43% discount on an FY25e P/E basis. We initiate coverage with a valuation of QAR1.22 per share, approximately c 40% above the current share price.
Click here to read the full report.
All reports published by Edison are available to download free of charge from its website
www.edisongroup.com
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
X www.x.com/edison_inv_res
YouTube www.youtube.com/edisonitv
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/249525
GE HealthCare is helping advance clinical and operational excellence in theranostics and molecular imaging through…
RLT_Angels Photo RLT Angels Association Further founding members include the European Association of Nuclear Medicine…
From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major…
Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined companyCRANFORD,…
Higher dose of Wegovy® provided average weight loss of 21% in people with obesity –…
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="2px" width="2px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="76px" width="200px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
